



UNIVERSITI PUTRA MALAYSIA

***PROTEIN EXPRESSION AND GENE ANALYSES OF HER2, NM23, AND
K-RAS IN GASTRIC CANCER AND HELICOBACTER PYLORI-
ASSOCIATED GASTRITIS***

NURULHAFIZAH SAMSUDIN

FPSK(M) 2012 54

**PROTEIN EXPRESSION AND GENE ANALYSES OF HER2, NM23, AND
K-RAS IN GASTRIC CANCER AND *HELICOBACTER PYLORI*-ASSOCIATED
GASTRITIS**

By

NURULHAFIZAH SAMSUDIN

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfilment of the Requirements for the Degree of
Master in Science**

January 2012

DEDICATION

I would like to dedicate my thesis to my beloved parents and family

Abstract of the thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

PROTEIN EXPRESSION AND GENE ANALYSES OF HER2, NM23, AND K-RAS IN GASTRIC CANCER AND *HELICOBACTER PYLORI*-ASSOCIATED GASTRITIS

By

NURULHAFIZAH SAMSUDIN

January 2012

Chair: Hairuszah Ithnin, MD, MPATH, AMM

Faculty: Faculty of Medicine and Health Sciences

Gastric cancer is ranked as the fourth most common cancer worldwide and the seventh most common cancer in the Malaysian population. Due to its vague and nonspecific symptoms, over 80% of gastric cancer cases were detected in advanced stage, leading to poor survival rate in the patients. Increasing evidence have shown that studies on the molecular biology aspects of *Helicobacter pylori*-associated chronic gastritis, which is a precursor of gastric cancer, may improve the early diagnosis of gastric cancer. To date, the existing evidence, however, have yet to determine the specific molecular biomarkers that may assist in the diagnosis of early gastric cancer. This preliminary study was done to investigate the role of HER2, nm23 and K-Ras as possible molecular biomarkers in gastric cancer and *H. pylori*-associated chronic gastritis. A total of 32 cases of gastric cancer and 62 cases of *H. pylori*-associated chronic gastritis were analyzed using immunohistochemical staining to investigate the protein expressions of HER2, nm23

and K-Ras. Mutational analysis on 15 cases of gastric cancer and 10 cases of *H. pylori*-associated chronic gastritis with prominent alterations in protein expressions was performed using polymerase chain reaction and direct sequencing. Our study demonstrated significant increase in the protein expression of nm23 in 62.5% (20/32) of gastric cancer and 33.9% (21/62) *H. pylori*-associated chronic gastritis and K-Ras in 62.5% (20/32) of gastric cancer and 24.1% (15/62) of *H. pylori*-associated chronic gastritis using Mann-Whitney U test ($P < 0.05$). The HER2 was overexpressed in 25.0% (8/32) cases of gastric cancer. However, none of the *H. pylori*-associated chronic gastritis (0.0%; 0/62) showed HER2 positivity. Using Spearman's rank correlation, age was significantly correlated with the nm23 expression in *H. pylori*-associated chronic gastritis ($P = 0.002$). Gender was significantly correlated with the K-Ras expression in gastric cancer ($P=0.026$). For the mutational analysis, no mutation was detected in the HER2 and K-Ras gene. Only one gastric cancer case (6.7%) showed a genetic variation with a C $\rightarrow$ A transition in the exon 1 of the nm23 gene. In conclusion, our findings suggest that nm23 and K-Ras may play role as possible early biomarkers in gastric cancers and precancerous lesions since significant increase was observed in their protein expressions. However, the absence or low incidence of mutations may indicate that mutations in HER2, nm23 or K-Ras gene have insignificant role in the progression of gastric cancer. Further studies should be performed to further elucidate the role of HER2, nm23 and K-Ras as biomarkers in gastric cancer.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia
sebagai memenuhi keperluan untuk ijazah Master Sains

**EKSPRESI PROTEIN DAN ANALISIS GEN HER2, NM23, DAN K-RAS
DALAM KANSER PERUT DAN *HELICOBACTER PYLORI*- GASTRITIS**

Oleh

NURULHAFIZAH SAMSUDIN

Januari 2012

Pengerusi: Hairuszah Ithnin, MD, MPATH, AMM

Fakulti: Fakulti Perubatan dan Sains Kesihatan

Kanser perut telah disenaraikan sebagai kanser keempat tertinggi di dunia dan kanser ketujuh tertinggi di kalangan penduduk Malaysia. Oleh kerana simptomnya yang samar dan tidak spesifik, lebih 80% kes kanser perut dikesan di peringkat akhir, membawa kepada kadar survival pesakit yang rendah. Peningkatan bukti yang menunjukkan bahawa kajian tentang aspek biologi molekul berkaitan *Helicobacter pylori*-gastritis kronik, yang mana merupakan prekursor kanser perut, boleh membantu dalam meningkatkan diagnosis awal kanser perut. Sehingga kini, bukti-bukti yang sedia ada, bagaimanapun, masih belum dapat menentukan biomarker molekular khusus yang boleh membantu di dalam diagnosis awal kanser perut. Kajian permulaan kami ini dilakukan untuk menyiasat peranan HER2, nm23 dan K-Ras sebagai calon biomarker molekular bagi kanser perut dan *H. Pylori*-gastritis kronik. Sebanyak 32 kes kanser perut dan 62 kes *H. Pylori*-gastritis kronik telah dianalisis menggunakan teknik immunohistokimia

untuk mengkaji ekspresi protein HER2, nm23 dan K-Ras. Analisis mutasi pada 15 kes kanser perut dan 10 kes *H. Pylori*-gastritis kronik yang menunjukkan perubahan yang jelas dalam ekspresi protein dilakukan dengan menggunakan teknik polimerase chain reaction dan sekuensing-langsung. Kajian kami menunjukkan peningkatan ketara di dalam ekspresi nm23 dalam 62.5% (20/32) kanser perut dan 33.9% (21/62) *H. Pylori*-gastritis kronik dan K-Ras dalam 62.5% (20/32) kanser perut dan 24.1% (15/62) *H. Pylori*-gastritis kronik berdasarkan analisa Mann-Whitney U ($P < 0.05$). Peningkatan ekspresi HER2 telah dilihat dalam 25.0% (8/32) kes kanser perut. Walau bagaimanapun, tiada kes *H. Pylori*-gastritis kronik yang menunjukkan kepositifan bagi HER2 (0.0%; 0/62). Berdasarkan analisa kolerasi Spermann, umur menunjukkan perkaitan jelas dengan ekspresi nm23 dalam *H.pylori*-gastritis kronik ($P=0.002$). Jantina menunjukkan perkaitan jelas dengan ekspresi KRAS dalam kanser perut ($P = 0.026$). Untuk analisis mutasi, tiada sebarang mutasi dikesan dalam gen HER2 dan KRAS. Hanya satu kes kanser perut (6.7%) menunjukkan variasi genetik dengan peralihan C $\rightarrow$ A dalam exon 1 bagi gen nm23. Sebagai kesimpulan, penemuan kami menunjukkan bahawa nm23 dan K-Ras mungkin memainkan peranan sebagai biomarker bagi kanser perut tahap awal dan juga luka tahap pra-kanser sepertimana yang telah diperhatikan dalam peningkatan ekspresi protein-protein tersebut. Walau bagaimanapun, kajian kami juga membuktikan bahawa ketiadaan atau kejadian mutasi yang rendah menunjukkan bahawa mutasi dalam gen HER2, nm23 atau K-Ras mempunyai peranan kurang penting dalam perkembangan kanser perut. Kajian lanjut perlu dilakukan bagi menjelaskan lagi peranan HER2, nm23 dan K-Ras biomarker dalam kanser perut.

ACKNOWLEDGEMENTS

Thank you. All praise due to Allah, Lord of the Universe; the Compassionate, the Merciful. His blessings have given me the strength to complete this study successfully.

First and foremost, I would like to extend my deepest appreciation and gratitude to my supervisor, Associate Professor Dr. Hairuszah Ithnin, for her valuable support and guidance throughout the research. She has always shrewd insight and given valuable detailed suggestions and comments which have greatly guided me to improve my work and create a better version of my thesis manuscripts. I am grateful to have such a nice and helpful supervisor.

I would also like to extend my sincere appreciation to the other members of my supervisory committee, Dr Maizura Ithnin and Dr. Razana Mohd Ali. Dr Maizura Ithnin has given me innumerable advice and guidance especially on the mutational analysis. Sincere appreciation is extended to Dr. Razana Mohd Ali for guiding me with her thoughtfulness and constructive advices. Special thanks to Dr Arni Talib from the General Hospital of Kuala Lumpur for her willingness to allow me to collect samples from the hospital.

I would like to devote my deepest gratitude to my respected parents, Samsudin Bahatom and Morsidah Elias, and my beloved family members for their unlimited love,

understandings and blessings. I knew they never failed to mention my name in their prayers. I will always remember theirs in mine.

To my friends, lab mates and lab staffs, I would like to give my heartfelt thanks for always be there helping me, especially always willing to stay late or come during those uncountable weekends so that I could finish my lab works. I am grateful to have friends who always listen, care, understand and share. I owe my deepest gratitude to them all.

Thank you very much.

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the supervisory committee were as follows:

Hairuszah Ithnin, MD, MPATH, AMM

Associate Professor & Consultant Pathologist
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Razana Mohd Ali, MD, MPATH, AMM

Lecturer & Consultant Pathologist
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Maizura Ithnin, PhD

Research Officer
Advanced Biotechnology and Breeding Centre (ABBC)
Biology Division
Malaysian Palm Oil Board
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

DECLARATION

I declare that the thesis is my original work except for quotations and citations which have been dully acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.

NURULHAFIZAH SAMSUDIN

Date: 26 January 2012

TABLE OF CONTENTS

	Page
DEDICATION	ii
ABSTRACT	iii
ABSTRAK	v
ACKNOWLEDGEMENTS	vii
APPROVAL	ix
DECLARATION	xi
LIST OF TABLES	xviii
LIST OF FIGURES	xx
LIST OF APPENDICES	xxiii
LIST OF ABBREVIATIONS	xxiv
CHAPTER	
1 INTRODUCTION	1
1.1 Background	1
1.2 Problem statement	5
1.3 Research hypothesis	5
1.4 Research objectives	6
1.4.1 General objective	6
1.4.2 Specific objectives	6
2 LITERATURE REVIEW	7
2.1 Anatomy of the stomach	7
2.1.1 Gross (macroscopic) anatomy	7
2.1.2 Microscopic anatomy	9
2.1.2.1 Cardiac-type mucosa	9
2.1.2.2 Fundic-type mucosa	9
2.1.2.3 Antral-type mucosa	10
2.2 Gastric cancer	12
2.2.1 Introduction	12

2.2.2	Types of gastric cancer	13
2.2.2.1	Adenocarcinoma	13
2.2.2.2	Lymphoma	16
2.2.2.3	Mesenchymal tumors	17
2.2.2.4	Endocrine tumors	17
2.2.3	Cause and risk factor	18
2.2.4	Gastric cancer diagnosis	19
2.2.5	Staging of gastric cancer	20
2.2.6	Prognosis	21
2.2.7	Treatments	23
2.3	<i>Helicobacter pylori</i>	25
2.3.1	Introduction to the bacteria	25
2.3.2	Pathogenicity properties	26
2.3.2.1	Vacuolating cytotoxin (VacA)	26
2.3.2.2	Pathogenicity island (cagPAI)	26
2.3.3	Role of <i>H. pylori</i> in carcinogenesis	27
2.4	Biomarkers in gastric cancer	29
2.4.1	Introduction to cancer biomarkers	29
2.4.2	HER2	30
2.4.3	nm23	32
2.4.4	K-Ras	35
2.4.5	HER2, nm23 and K-Ras in the MAPK/ERK pathway	38
2.4.6	HER2, nm23 and K-Ras involvement in precancerous lesions	40

3 MATERIALS AND METHODS 43

3.1	Sample collection	43
3.1.1	Ethics approval	43
3.1.2	Methods of sample collection	43
3.1.2.1	Inclusion criteria	44
3.1.2.2	Exclusion criteria	44

3.1.3	Sample calculation for protein expression study	44
3.2	Hematoxylin and Eosin (H&E) staining	46
3.2.1	Standard H&E protocol	46
3.3	Immunohistochemistry	47
3.3.1	Tissue preparation	47
3.3.2	Standard immunohistochemistry	48
3.3.2.1	Immunohistochemistry of HER2	50
3.3.2.2	Immunohistochemistry of nm23	50
3.3.2.3	Immunohistochemistry of K-Ras	51
3.3.3	Evaluation of immunohistochemical staining	51
3.3.3.1	Scoring system for HER2	51
3.3.3.2	Scoring system for nm23	52
3.3.3.3	Scoring system for K-Ras	53
3.3.4	Statistical analysis	54
3.4	DNA analysis	58
3.4.1	Sample selection	58
3.4.2	Tissue preparation for DNA extraction	58
3.4.3	DNA extraction	59
3.4.4	Nanodrop spectrophotometer	61
3.4.5	Polymerase chain reaction (PCR)	61
3.4.5.1	Preparation of PCR mixture	61
3.4.5.2	PCR reaction	62
3.4.6	Gel electrophoresis	64
3.4.7	DNA purification from gel	65
3.4.8	Direct sequencing	66
3.4.9	Post-sequencing analysis	66
3.5	Flow chart	67
4	RESULTS	68
4.1	Sample distribution	68
4.1.1	Gastric cancer	68

4.1.2	<i>Helicobacter pylori</i> -associated chronic gastritis	70
4.2	Analysis of tissue morphology	71
4.3	Analysis of HER2, nm23 and K-Ras protein expression in gastric cancer and <i>H. pylori</i> -associated chronic gastritis	74
4.3.1	HER2 immunohistochemical analysis	74
4.3.1.1	HER2 protein expression in gastric cancer	74
4.3.1.2	HER2 protein expression in <i>H. pylori</i> -associated chronic gastritis	76
4.3.1.3	Correlation of HER2 immunoreactivity among cases	77
4.3.1.4	Association of the HER2 expression with clinicopathological features	80
4.3.2	nm23 immunohistochemical analysis	83
4.3.2.1	Analysis of nm23 protein expression in gastric cancer	83
4.3.2.2	Analysis of nm23 protein expression in <i>H. pylori</i> -associated chronic gastritis	85
4.3.2.3	Correlation of nm23 immunoreactivity among cases	86
4.3.2.4	Association of the nm23 expression with clinicopathological features	88
4.3.3	K-Ras immunohistochemical analysis	91
4.3.3.1	Analysis of K-Ras protein expression in gastric cancer	91
4.3.3.2	Analysis of K-Ras protein expression in <i>H. pylori</i> -associated chronic gastritis	93
4.3.3.3	Correlation of K-Ras immunoreactivity among cases	95
4.3.3.4	Association of the K-Ras expression with clinicopathological features	97

4.3.4	Correlation among the HER2, nm23 and K-Ras protein expressions in gastric cancer and <i>H. pylori</i> -associated chronic gastritis	100
4.4	Analysis of mutation	101
4.4.1	Assessment of nucleic acid quality from DNA extraction	101
4.4.2	HER2 analysis	104
4.4.2.1	Confirmation of amplified HER2 fragment following PCR reactions	104
4.4.2.2	Direct sequencing to identify HER2 mutation	107
4.4.3	nm23 analysis	109
4.4.3.1	Confirmation of amplified nm23 fragment following PCR reactions	109
4.4.3.2	Direct sequencing to identify nm23 mutation	112
4.4.4	K-Ras analysis	114
4.4.4.1	Confirmation of amplified K-Ras fragment following PCR reactions	114
4.4.4.2	Direct sequencing to identify K-Ras mutation	116
5	DISCUSSION	117
5.1	Analysis of HER2, nm23 and K-Ras protein expression	117
5.1.1	HER2 immunohistochemical analysis	117
5.1.1.1	HER2 protein expression in gastric cancer	117
5.1.1.2	HER protein expression in <i>H. pylori</i> -associated chronic gastritis	120
5.1.1.3	Clinicopathological correlation analysis of HER2 immunoreactivity	122
5.1.2	nm23 immunohistochemical analysis	125
5.1.2.1	nm23 protein expression in gastric cancer	125

5.1.2.2	nm23 protein expression in <i>H. pylori</i> -associated chronic gastritis	127
5.1.2.3	Clinicopathological correlation analysis of nm23 immunoreactivity	128
5.1.3	K-Ras immunohistochemical analysis	131
5.1.3.1	K-Ras protein expression in gastric cancer	131
5.1.3.2	K-Ras protein expression in <i>H. pylori</i> -associated chronic gastritis	132
5.1.3.3	Clinicopathological correlation analysis of K-Ras immunoreactivity	133
5.2	Correlation among HER2, nm23 and K-Ras expression	136
5.3	HER2, nm23 and K-Ras mutation analysis	139
5.3.1	Analysis of HER2 mutation	139
5.3.2	Analysis of nm23 mutation	140
5.3.3	Analysis of K-Ras mutation	142
6	CONCLUSION AND FUTURE RECOMMENDATIONS	145
5.1	Conclusion	145
5.2	Future recommendations	148
	REFERENCES	149
	APPENDICES	167
	BIODATA OF STUDENT	189
	LIST OF PUBLICATION	190
	LIST OF PROCEEDINGS	191

LIST OF TABLES

Table	Page
2.1 List of modification for the 7 th edition of AJCC TNM staging system	21
2.2 List of cancer markers with a known plasma concentration or used clinically	30
3.1 Scoring system for HER2 immunohistochemistry	52
3.2 Scoring system for nm23 immunohistochemistry	53
3.3 Scoring system for K-Ras immunohistochemistry	53
3.4 Forward and reverse primers for HER2, nm23 and K-Ras	62
4.1 Gastric cancer patient characteristics	69
4.2 <i>H. pylori</i> -associated chronic gastritis patient characteristics	70
4.3 Descriptive study for HER2 immunoreactivity	78
4.4 Mann-Whitney U test to compare significant difference of HER2 expression in gastric cancer and <i>H. pylori</i> -associated chronic gastritis	79
4.5 Correlation between HER2 in gastric cancer and clinicopathological parameters	81
4.6 Correlations between population characteristics and HER2 immunohistochemistry in <i>H. pylori</i> -associated chronic gastritis	82
4.7 Descriptive study for nm23 immunoreactivity	87
Mann-Whitney U test to compare significant difference of nm23	

4.8	expression in gastric cancer and <i>H. pylori</i> -associated chronic gastritis	88
4.9	Correlation between nm23 immunoreactivity in gastric cancer and several clinicopathological parameters	89
4.10	Correlations between population characteristics and nm23 in <i>H. pylori</i> -associated chronic gastritis	90
4.11	Descriptive study for K-Ras immunoreactivity	95
4.12	Mann-Whitney U test to compare significant difference of nm23 expression in gastric cancer and <i>H. pylori</i> -associated chronic gastritis	96
4.13	Correlation between K-Ras immunoreactivity in gastric cancer and several clinicopathological parameters	98
4.14	Correlations between population characteristics and K-Ras in <i>H. pylori</i> -associated chronic gastritis	99
4.15	Correlation among the total score of HER2, nm23 and K-Ras immunoreactivity	100
4.16	Quantitative DNA assessment by Nanodrop 1000 Spectrophotometer	101

LIST OF FIGURES

Figure	Page
2.1 Anatomy of the stomach	7
2.2 Histology of the stomach	11
2.3a Japanese classification of early gastric cancer	16
2.3b Borrmann classification of advanced gastric cancer	16
2.4 Involvement of HER2, nm23 and K-Ras in MAPK/ERK signaling pathway for cell growth and differentiation	38
2.5 Genetic and epigenetic alterations in intestinal-type gastric cancer	40
3.1 Immunohistochemical scoring guide for HER2	55
3.2 Immunohistochemical scoring guide for nm23	56
3.3 Immunohistochemical scoring guide for K-Ras	57
3.4 Flow-chart on methodology	67
4.1 Histology of gastric cancer	72
4.2 Morphological changes in <i>H. pylori</i> -associated chronic gastritis.	73
4.3 The presence of <i>H. pylori</i> in the <i>H. pylori</i> -associated chronic gastritis	73
4.4 Status of HER2 immunoreactivity and positivity	74
4.5 Immunohistochemical expression of HER2 in gastric cancers	75

4.6	Status of HER2 positivity in <i>H. pylori</i> -associated chronic gastritis	76
4.7	HER-2 IHC expression in <i>H. pylori</i> -associated chronic gastritis	77
4.8	Box-plot for HER2 immunoreactivity	79
4.9	Status of nm23 positivity in gastric cancer.	83
4.10	Immunohistochemical expression of nm23 in gastric cancers	84
4.11	Status of nm23 positivity in <i>H. pylori</i> -associated chronic gastritis	85
4.12	nm23 expression in <i>H. pylori</i> -associated chronic gastritis	86
4.13	Box-plot for nm23 immunoreactivity	88
4.14	Status of K-Ras positivity in gastric cancer	91
4.15	Immunohistochemical expression of K-Ras in gastric cancers	92
4.16	Status of K-Ras positivity in <i>H. pylori</i> -associated chronic gastritis	93
4.17	Representative of immunohistochemical staining of K-Ras	94
4.18	Box-plot for K-Ras immunoreactivity	96
4.19	Qualitative assessment of DNA absorbance plot using a Nanodrop 1000 spectrophotometer	102
4.20	Absorbance plot for three replicates of DNA extraction from a sample to examine the reproducibility of the DNA extraction	103
4.21	PCR amplification bands for 15 samples of gastric cancer for HER2 gene analysis	105
4.22	PCR amplification bands for 10 <i>H. pylori</i> -associated chronic	106

gastritis cases for HER2 gene analysis

4.23	PCR amplification bands for 5 cases of normal gastric tissues for HER2 gene analysis	106
4.24	Sequence alignments and electropherograms of a region on HER2 DNA fragment	108
4.25	Amplification bands for 15 samples of gastric cancer for nm23 gene analysis	110
4.26	nm23 fragment separation for <i>H. pylori</i> -associated chronic gastritis cases	111
4.27	nm23 fragment separation for normal gastric tissues.	111
4.28	Sequence alignments and electropherograms of a region on nm23 DNA fragment	112
4.29	Human nm23 exon 1 gene sequence.	113
4.30	K-Ras analysis in gastric cancer	114
4.31	K-Ras fragment separation for <i>H. pylori</i> -associated chronic gastritis.	115
4.32	Gel electrophoresis for K-Ras fragment from normal gastric tissues	115
4.33	Representative of sequence alignments of a region on K-Ras DNA fragment	116

LIST OF APPENDICES

Appendix	Page
A1	Ethics approval 164
A2	Ethics approval 165
A3	Ethics approval 166
B	Solutions and reagents preparation 167
C1	Hematoxylin & Eosin staining protocol 169
C2	Immunohistochemical staining protocol 170
C3	DNA extraction protocol 172
C4	Polymerase chain reaction (PCR) protocol 174
C5	Gel electrophoresis protocol 176
C6	DNA extraction from gel protocol 178
D1	DNA sequence alignment; Exon 20 of HER2 gene 180
D2	DNA sequence alignment; Exon 1 of nm23 gene 182
D3	DNA sequence alignment; Exon 2 of K-Ras gene 184

LIST OF ABBREVIATIONS

g	Gram
ng	Nanogram
μl	Microlitre
ml	Millilitre
cm	Centimetre
μm	Micrometer
bp	Base pair (nucleotide)
rpm	Revolutions per minute
°C	Degree Celsius
%	Percentage
<	Less than
>	More than
≥	Equal to or more than
±	Approximately
=	Equal to

/	Out of
-ve	Negative
+ve	Positive
<i>et al.</i>	And others
AJCC	American Joint Committee on Cancer
APC	Adenomatous polyposis coli
cagPAI	Pathogenicity island
CT	Computed tomography
CRC	Clinical Research Center, Malaysia
DNA	Deoxyribonucleotide acid
ECL	Enterochromaffin-like
EGFR	Epidermal growth factor receptor
EMR	Endoscopic mucosal resection
ERK	Extracellular regulated kinase
EUS	Endoscopicultrasonography
FFPE	Formalin-fixed, paraffin embedded
FISH	Fluorescence <i>in situ</i> hybridization

GANT	Gastrointestinal autonomic nerve tumor
GC	Gastric cancer
GIST	Gastrointestinal stromal tumors
GTP	Guanosine triphosphate
<i>H. pylori</i>	<i>Helicobacter pylori</i>
HER2	Human Epidermal Growth Factor Receptor 2
HIER	Heat induced epitope retrieval
HPCG	<i>H. pylori</i> -associated chronic gastritis
IARC	The International Agency for Research
K-Ras	V-Ki-ras2 Kirsten rat sarcoma viral oncogene
KSR	Kinase suppressor of Ras
MAPK	Mitogen-activated protein kinase
MEK	Methyl ethyl ketone
MSI	Microsatellite instability
NIH	National Institute of Health
nm23	Human nonmetastatic clone 23
OGDS	Oesophagogastrroduodenoscopy

PCR	Polymerase chain reaction
PI3K-Akt	Phosphoinositide 3-kinase/Akt
PMNs	Polymorphonuclear leukocyte
QV	Quality value
Ras	Rat Sarcoma
ROS	Reactive oxygen species
RTK	Receptor tyrosine kinase
SEER	The United States' Surveillance, Epidemiology, and End Results
TNM	Depth of tumor invasion; involvement of local or distant lymph nodes; M distant metastasis
UICC	Union for International Cancer Control
VacA	Vacuolating cytotoxin
WHO	World Health Organization

CHAPTER I

INTRODUCTION

1.1 Background

Gastric cancer refers to a malignant growth in the stomach. It may develop as a result of abnormal cell division due to mutations of certain genes, or a prolonged exposure towards carcinogenic agents. Based on the cellular origin of the growth, gastric cancer can further be classified into several types including gastric adenocarcinoma, gastric lymphoma and gastric sarcoma.

Gastric adenocarcinoma is the malignant growth that originates from the glandular cells of the stomach. Adenocarcinoma of the stomach accounts for approximately 90% of gastric cancer (Rotterdam & Enterline, 1989; Kelley & Duggan, 2003) and 10% of cancers worldwide (Ferlay *et al.*, 2004). It can be divided into two groups based on Lauren's classification: intestinal-type adenocarcinoma and diffuse-type adenocarcinoma (Lauren, 1965; Roukos *et al.*, 2002). The remaining of the percentage comprised of gastric lymphoma (about 2-7%) and gastric sarcoma (Rotterdam & Enterline, 1989). Gastric lymphoma originates from lymphoid cells, whereas, gastric sarcoma originates from mesenchymal tissues.

Gastric cancer is particularly common in countries like Korea, Japan, South America, Ukraine and Russian Federation (Bertuccio *et al.*, 2009). It is ranked as the

fourth most common cancer worldwide and is the seventh most common cancer affecting the local population in Malaysia (Parkin *et al.*, 2005; Malaysian Cancer Statistics., 2006). It is not as common as other types of cancer but it continues to carry high morbidity rate. Its nonspecific symptoms that resemble other benign gastric conditions such as vomiting, indigestion, and stomach discomfort often cause the cancer to develop undetected. Hence, more complex investigations are needed for proper diagnosis.

Individuals with high risk factor for gastric cancer include being male, elderly, cigarette smokers and patients suffering from chronic gastritis with intestinal metaplasia or pernicious anemia (Kelley & Duggan, 2003). In addition to that, long-term *Helicobacter pylori*-associated chronic gastritis is also believed to be a precursor of gastric cancer. The International Agency for Research on Cancer (IARC) has categorized *H. pylori* in Group 1 carcinogen (IARC, 1994). Its infection is allegedly responsible for 63% of all worldwide cases of non-cardia gastric cancer and may increase the incidence rate of gastric cancer by a factor of 6 (Parkin *et al.*, 2005). The infected normal tissue may progress into several intermediate stages like chronic gastritis, gastric atrophy, intestinal metaplasia, dysplasia and finally gastric cancer (Correa & Shiao, 1994; Milne & Offerhaus, 2010).

There is a need to search for biomarkers to allow the detection of cancer especially at early stage. This is proven important since in Malaysia alone, it is estimated that 82% of gastric cancer patients were diagnosed with Stage IV (Kandasami

et al., 2003). In general, for solid cancers such as gastric cancer, the prognosis and survival depends mainly on stage at diagnosis (Sant *et al.*, 2009). Analysis of gastric cancer biomarkers in patients with *H. pylori*-associated chronic gastritis may prove crucial since *H. pylori*-associated chronic gastritis is a precursor for gastric cancer and approximately 50% of the world population and 90% of the developing countries population are infected by the bacteria (World Cancer Report, 2008).

In this study, we analyzed Human epidermal growth factor receptor 2 (HER2), Nonmetastatic protein-23 (nm23), and v-Ki-ras2 Kirsten rat sarcoma viral oncogene (K-Ras) in gastric cancer and *H. pylori*-associated chronic gastritis. These proteins are involved in the Mitogen-activated protein kinase (MAPK/ERK) pathway and are responsible in facilitating and promoting cell division in normal tissue. In cancer, HER2 and K-Ras were found to have the ability to promote neoplasm due to their oncogenic properties (Juhl *et al.*, 1997; Gong *et al.*, 1999). Similarly, although nm23 protein has been recognized as a metastatic suppressor protein, a few studies have discovered its role in cancer progression and suppression of early step of carcinogenesis (Stahl *et al.*, 1991; Chow *et al.*, 2000). Hence, the aim of our study was to evaluate the status of HER2, nm23 and K-ras protein expression in gastric cancer.

The protein and genetic analysis of HER2, nm23, and K-Ras in gastric cancer have never been studied in Malaysian population. Moreover, previous findings have found that mutations in signalling components downstream of the MAPK/ERK pathway, such as mutations in HER2, nm23, and K-Ras, may slow or stop suppressive

therapy in gastric cancer (Roukos, 2010). Therefore, further understanding of HER2, nm23, and K-Ras is important since alterations in these proteins might have significant effects on gastric cancer progression and therapy.

From this study, analysis of protein expression may give some understanding on the role of *H. Pylori*-associated chronic gastritis as precursors for gastric cancer. In addition to that, genetic analysis of HER2, nm23, and K-Ras may provide some information on possible genetic alterations of these genes in gastric cancer. Correlation between protein and genetic analyses of these genes may provide some preliminary information that might be important for future research especially on diagnostic, prognostic and therapeutic biomarkers of gastric cancer.

In conclusion, molecular biomarker research on HER2, nm23 and K-Ras may open the possibility for early gastric cancer detection. Problem relating to gastric cancer is that due to late diagnosis of gastric cancer, patient survival rate is still relatively very low despite rapid improvements in cancer drugs and therapy. In fact, even with substantial increases in the cancer drugs or therapy, little is known about the effectiveness of the new treatment on different types of patients' genetics and backgrounds without the use of cancer biomarkers. Hence, in this study, we analyzed HER2, nm23 and K-Ras as possible biomarkers in gastric cancer. We hypothesize that the comparison of analyses on HER2, nm23 and K-Ras in gastric cancer cases with *H. pylori*-associated chronic gastritis cases could lead to the discovery of possible biomarkers for the detection of early gastric cancer.

1.2. Problem statement

The progression of *H. pylori*-associated chronic gastritis into gastric cancer, through several intermediate stages like gastric atrophy, intestinal metaplasia, and dysplasia, has been proposed long ago by Correa & Shiao (1994) and Milne & Offerhaus (2010). Many current studies are focusing on the molecular biomarkers for gastric cancer in order to understand the underlying factors that contribute to carcinogenesis. However, up until now, there is still no appropriate biomarker for early diagnosis of gastric cancer.

1.3. Research hypothesis

- 1.3.1 If HER2, nm23, and K-Ras have role as early molecular markers, then their protein expression should show significant increase in both gastric cancer and *H. pylori*-associated chronic gastritis.
- 1.3.2 If *H. pylori* infection has role in inducing activating mutation, then activating mutation may be the reason for HER2, nm23 and K-Ras overexpression.

1.4. Research Objectives

1.4.1 General objective:

To determine HER2, nm23, and K-Ras role as possible diagnostic biomarkers in gastric cancer.

1.4.2 Specific Objectives:

- a. To determine protein expressions of HER2, nm23, and K-Ras using immunohistochemical analysis in gastric cancer and *H. pylori*-associated chronic gastritis.
- b. To identify genetic alterations in HER2, nm23, and K-Ras by using gel electrophoresis and DNA sequencing in gastric cancer and *H. pylori*-associated chronic gastritis.
- c. To correlate the protein expressions and genetic alterations of HER2, nm23, and K-Ras in gastric cancer and *H. pylori*-associated chronic gastritis.

REFERENCES

- Abe, M., Yabumoto, E., Takahashi, M., Tobe, T. & Mori, K.J. (1974). Intraoperative radiotherapy of gastric cancer. *Cancer*. 34:2034-2041.
- Allen, J.C. (2011). Sample size calculation for two independent groups: A useful rule of thumb. *Proceedings of Singapore Healthcare*. 20(2): 138-140.
- An, R., Chu, Y., Tian, C., Dai, X., Chen, J., Shi, Q., Han, J., & Dong, X. (2008). Overexpression of nm23-H1 in HeLa cells provides cells with higher resistance to oxidative stress possibly due to raising intracellular p53 and GPX1. *Acta Pharmacologica Sinica*. 29(12):1451-1458.
- An, Y.J., Kang, T.H., Choi, M.G., Noh, J.H., Sohn, T.S. & Kim, S. (2008). Borrmann type IV: An independent prognostic factor for survival in gastric cancer. *Journal of Gastrointestinal Surgery*. 12:1364-1369.
- Antonacopoulou, A.G., Tsamandas, A.C., Petsas, T., Liava, A., Scopa, C.D., Papavassil, A.G. & Kalofonos, H.P. (2008). EGFR, HER-2 and COX-2 levels in colorectal cancer. *Histopathology*. 53:698-706.
- Bal, A., Joshi, K, Logasundaram, R., Radotra, B.D. & Singh, R. (2008). Expression of nm23 in the spectrum of pre-invasive, invasive and metastatic breast lesions. *Diagnostic Pathology*. 3:23
- Barros-Silva, J.D., Leitao, D., Afonso, L., Vieira, J., Dinis-Ribeiro, M, Fragoso, M, Bento, M.J., Santos, L., Ferreira, P., Rego, S., Brandao, C., Carneiro, F., Lopes, C., Schmitt, F. & Teixeira, M.R. (2009). Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. *British Journal of Cancer*. 100:487-493.
- Baselga, J. & Swain, S.M. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. *Nature Reviews cancer*. 9(7):463-475.
- Baselga, J. (2001). The EGFR as a target for anticancer therapy focus on cetuximab. *European Journal of Cancer*. 37(4):16-22.
- Bertuccio, P., Chatenoud, L., Levi, F., Praud, D., Ferlay, J. & Negri, E. (2009). Recent patterns in gastric cancer: A global overview. *International Journal of Cancer*. 125:666-673.
- Braun, S., Mauch, C., Boukamp, P. & Werner, S. (2007). Novel roles of NM23 proteins in skin homeostasis, repair and disease. *Oncogene*. 26:532-542.
- Brenner, H., Bode, G., & Boeing, H. (2000). *Helicobacter pylori* infection among offspring of patients with stomach cancer. *Gastroenterology*. 118:31-35.

- Brenner, H., Rothenbacher, D., & Arndt, V. (2009). Epidemiology of stomach cancer. *Cancer Epidemiology*. 472:467-477.
- Brooks, J.J. & Enterline, H.T. (1983). Primary gastric lymphomas: a clinicoopathologic study of 58 cases with long-term follow-up and literature review. *Cancer*. 51:701-711.
- Brown, M.D., & Sacks, D.B. (2009). Protein scaffolds in MAP kinase signalling. *Cellular signalling*. 21:462-469.
- Bryan, J., Bigam, D.L., Cass, C., Mackey, J.R., Joy, A.A., & Hamilton, S.M., (2005). Gastric adenocarcinoma. Review and considerations for future directions. *Annals of Surgery*. 241(1):27-39.
- Calipel, A., Lefevre, G., Pouponnot, C., Mouriaux, F., Eychene, A., & Mascarelli, F. (2003). Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. *Journal of Biological Chemistry*. 278: 42409-42418.
- Calle, E.E., Rodriguez, C., Walker-Thurmond, K., & Thun, M.J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *The New England Journal of Medicine*. 348:1625-1638.
- Caristo, E., Parola, A., Rapa, A., Vivenza, D., Raselli, B., Dondi, E., Boldorini, R. & Oderda, G. (2008). Clarithromycin resistance of *H. pylori* strains isolated from children' gastric antrum and fundus as assessed by fluorescent in-situ hybridization and culture on four-sector agar plates. *Helicobacter*. 13(6):557-563.
- Chen, C.Y., Hsu, J.S., CHyang, D., Kang, W.Y., Hsieh, J.S., Jaw, T.S., Wu, M.T. & Liu, G.C. (2007). Gastric cancer: preoperative local staging with 3D multi-detector row CT-correlation with surgical and histopathologic results. *Radiology*. 242(2):472-482.
- Chow, N.W., Liu, H.S., & Chan, S.H. (2000). The Role of nm23-H1 in the Progression of Transitional Cell Bladder Cancer. *Clinical Cancer Research*. 6:3595-3599.
- Churin, Y., Al-Ghoul, L., Kepp, O., Meyer, T.F., Birchmeier, W. & Nanmann, M. (2003). *Helicobacter pylori* CagA protein targets the c-Met receptor and enhances the motogenic response. *The Journal of Cell Biology*. 161(2):249-255.
- Cipollini, G., Moretti, A., Ghimenti, C., Vicava, P., Bevilacqua, G. And Caligo, M.A. (2000). Mutational analysis of the NM23.H1 gene in human breast cancer. *Cancer Genetics & Cytogenetics*. 121(2):181-185.
- Clemens, M. R. (1991). Free radicals in chemical carcinogenesis. *Wiener Klinische Wochenschrift*. 69: 1123-1134.
- Correa, P. & Shiao, Y.H. (1994). Phenotypic and genotypic events in gastric carcinogenesis. *Cancer Research*. 54: 1941-1943.

- Covacci, A., Telford, J.L., Del Giudice, G., Personnet, J & Rappuoli, R. (1999). *Helicobacter pylori* virulence and genetic geography. *Science*. 284:1328-1333.
- Cropp, C.S., Lidereau, R., Leone, A., Liscia, D., Cappa, A.P, Campbell, G., Barker, E., Le Doussal, V., Steeg, P.S. & Callahan, R. (1994). NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors. *Journal of National Cancer Institute*. 86:1167-1169.
- Crowley, L.V. (2010). *An introduction to human disease: Pathology and pathophysiology correlations (8th edition)*. Jones and Bartlett Publishers. Massachusetts, USA
- D'Elios, M.M., Montecucco, C. & de Bernard, M. (2009). VacA and HP-NAP, Ying and Yang of *Helicobacter pylori*-associated gastric inflammation. *Clinica Chimica Acta*. 381(1):32-38.
- Davies, G. R., Collins, C. E., Banatvala, N., Sheaff, M. T., Abdi, Y., Clements, L. & Rampton, D. S. (1994). A direct relationship between infective load of *Helicobacter pylori* and oxygen free radical production in antral mucosal biopsies. *Gut*. 29(5):419-424.
- De Lisi, S., Peralta, S., Arini, A., Simone, F. and Craxi, A. (2011). Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension. *Digestive and Liver Disease*. 43(1): 48-53.
- Dhar, D.K., Kubota, H., Tabara, H., Koto, T., Monden, N., Igarashi, M., Kohno, H., Nagasue, N. (1999). Nm23 in the primary and metastatic sites of gastric carcinoma. *Oncology*. 56:122-128.
- Dixon, M.F., Genta, R.M., Yardley, J.H. & Correa, P. (1996). Classification and grading of gastritis. The updated Sydney system. *The American Journal of Surgical Pathology*. 100:375-379.
- Dunn, K.L., Espino, P.S., Drobic, B., He, S. & Davies, J.R. (2005). The Ras-MAPK signal transduction pathway, cancer and chromatin remodelling, minireview. *Biochemistry and Cell Biology*. 83:1-14.
- Ebert, M. and Malfertheiner, P. (2005). *New developments in the management of gastric cancer. Digestive diseases clinical reviews*. Karger Publishers, Switzerland.
- Elagoz, S., Egilmez, R., Koyuncu, A., Muslehiddinoglu, A. & Arici, S. (2006). The intramucosal microvessel density and expression of bFGF and nm23-H1 in colorectal cancer. *Pathology Oncology Research*. 12(1):21-27.
- Elsborg, L. & Mosbech, J. (1979). Pernicious anemia as a risk factor in gastric cancer. *Acta Medica Scandinavica*. 206(1-6):315-318.

- English, J., Pearson, G., Wilsbacher, J., Swantek, J., Karandikar, M. & Xu, S., Cobb M.H. (1999). New insights into the control of MAPK kinase pathway. *Experimental Cell Research*. 25(1):255-270.
- Evans, D. J. Jr., Evan, D. G., Takemura, T., Nakano, H., Lampert, H. C., Graham, D. Y., Granger, D.N. & Kvietys, P. R. (1995). Characterization of *Helicobacter pylori* neutrophil-activating protein. *Infection and Immunity*. 63:2213-2220.
- Feigin A. (2004). Evidence from biomarkers and surrogate endpoints. *Neurotherapeutics*. 1(3):323-330.
- Ferlay, J., Bray, F., Pisani, P. & Parkin, M. (2004). Cancer incidence, mortality, and prevalence worldwide. *Globocan 2002*. Lyon: IARC.
- Floch, M.H., Kowdley, K., Pitchumoni, C.S., Floch, N.R., Rosenthal, R. & Scolapio, J. (2005). *Netter's Gastroenterology*. U.S.A: MediMedia, Inc.
- Fong, Y., Chou, S.J., Hung, K.F., Wu, H.T. & Kao, S.Y. (2008). An investigation of the differential expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan. *Journal of Chinese Medical Association*. 71(3):123-127.
- Fong, Y., Chou, S.J., Hung, K.F., Wu, H.T. and Kao, S.Y. (2008). An investigation of the differential expression of HER2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan. *Journal of Chinese Medical Association*. 71(3):123-127.
- Fujita, R., Jass, J.R., Kaminishi, M. & Schlemper, R.J (2006). *Early cancer of the gastrointestinal tract: Endoscopy, Pathology, and Treatment*. Tokyo: Springer.
- Gebert, B., Fischer, W. & Haas, R. (2004). The *Helicobacter pylori* vacuolating cytotoxin: from cellular vacuolation to immunosuppressive activities. *Reviews of Physiology, Biochemistry and Pharmacology*. 152:205-220.
- Giamas, G., Man, Y.L., Hirner, H., Bischof, J., Kramer, K., Khan, K., Lavina Ahmed, S.S., Stebbing, J. & Knippschild, U. (2010). Kinases as targets in the treatment of solid tumors. *Cellular Signalling*. 22:984-1002.
- Giles, G.R., Humphries, C., Mason, C. & Clark, C.G. (1969). Effect of pH changes on the cardiac sphincter. *Gut*. 10:852-856.
- Glimelius, B., Ekstrom, K., Hoffman, K., Graf, W., Sjoden, P.O., Haglund, U., Swensson, C., Enander, L.K., Linne, T., Sellsrom, H., Heuman, R. (1996). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. *Annals of Oncology*. 8(2):163-168.
- Gong, C., Mera, R., Bravo, J.C., Ruiz, B., Diaz-Escamilla R., Fontham, E.T.H., Correa, P. & Hunt, J.D. (1999). KRAS mutations predict progression of preneoplastic gastric lesions. *Cancer Epidemiology, Biomarkers and Prevention*. 8:167-171.

- Gospodarowics, M., Wittekind, C. & Sobin, L. (2009). TNM classification of malignant tumors-7th edition. Outline of changes between 6th and 7th edition, UICC.
- Grandis, J.R. & Sok, J.C. (2004). Signaling through the epidermal growth factor receptor during the development of malignancy. *Pharmacology & Therapeutics*. 102: 37–46.
- Gravalos, C. & Jimeno, A. (2008).** HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. *Annals of Oncology*. 19:1523-1529.
- Greene, F.L., Page, D.L. & Fleming, I.D. (2002) *AJCC cancer staging manual 6th edition*, New York: Springer-Verlag.
- Guan-zhen, Y., Ying, C., Can-rong, N., Guo-dong, W., Jian-xin, Q. & Jie-jun, W. (2007). Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1, and p53) in lymph node and liver metastases of gastric cancer. *International Journal of Experimental Pathology*. 88:175-183.
- Gursan, N., Albayrak, A., Gursan, M.S. & Keles, M. (2001). Gastric carcinomas in Erzurum region. *Turkish Journal of Gastroenterology*. 12(4)294-298.
- Halliwell, B. & Aruoma, O.I. (1991). DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian system. *FEBS Letters*, 281:9-19.
- Hamilton, S.R. & Aaltonen, L.A. (2000).** *World Health Organization Classification of Tumors, Pathology, and Genetics of Tumors of the Digestive System*. Lyon: IARC Press.
- Hanash, S.M., Pitteri, S.J. & Faca, V.M. (2008). Mining the plasma proteome for cancer biomarkers. *Nature* 453: 571-579.
- Hardwick, R.H., Barham, C.P. & Ozua, E. (1997). Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. *European Journal of Surgical Oncology*. 123:30-35.
- Hartsough, M.T. & Steeg, P.S. (2000). Nm23/nucleoside diphosphate kinase in human cancers. *Journal of Bioenergetics and Biomembranes*. 32:301-308.
- Hashim, D., Apostolova, M., Lavotskin, S., Goldstein, E., and Chorost, M. (2009). The evolution in the management of gastric lymphoma. *Gastroenterology Research*. |doi:10.4021/gr2009.09. 1312.
- Hayat, M.A. (2002). *Microscopy, immunohistochemistry, and antigen retrieval methods: Light and electron microscopy*. New York: Kluwer Academic Publishers
- Heitzmann, D. & Warth, R. (2008). Physiology and pathophysiology of potassium channels in gastrointestinal epithelia. *Physiological Reviews* 88:1119-1182.
- Herskovic, A., Martz, K., Al-Sarraf, M., Leichman, L., Brindle, J., Vaitkevicius, V., Cooper, J., Byhardt, R., Lawrence D. & Emami, B. (1992). Combined

chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *The New England Journal of Medicine* 326:1593-1598.

Hirsch, F.R., Varella-Garcia, M. & Cappuzzo, F. (2009). Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. *Oncogene*. 28:32–37.

Histopage. (n.d.). Retrieved August 17, 2011, from University of Delaware website: <http://www.udel.edu/biology/Wags/histopage/colorpage/ces/cescg1.GIF>

Hiyama, T., Haruma, K., Kitadai, Y., Masuda, H., Miyamoto, M., Tanaka, S., Yoshihara, M., Shimamoto, F. & Chayama, K. (2002). K-RAS mutation in *Helicobacter pylori*-associated chronic gastritis in patients with and without gastric cancer. *International Journal of Cancer*. 97:562-566.

Hoffman, M., Stoss, O., Shi, D., Buttner, R., Van De Vijer, M., Kim, W., Achial, A., Ruschoff, J. & Henkel, T. (2008). Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology*. 52(7):797-805.

Homo sapiens chromosome 17. (n.d.). Retrieved August 28, 2011, from NCBI website: <http://www.ncbi.nlm.nih.gov/nuccore/224589808?report=fasta>

Hong, W.K., Bast, R.C., Hait, W.N., Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Holland, J.F. & Ill, E.F. (2009). *Holland-Frei cancer medicine* 8. United States: American Association for Cancer Research (AACR) PMPH-USA.

Hongyo, T., Buzard, G.S., Palli, D., Weghorst, C.M., Amorosi, A., Galli, M., Caporaso, N.E., Fraumeni, J.F. Jr. & Rice, J.M. (1995). Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. *Cancer Research*. 55:2665-72.

Horak, C.E., Lee, J.H., Marshall, J.C., Shreeve, S.M. & Steeg, P.S. (2008). The role of metastasis suppressor genes in metastatic dormancy. *Acta Pharmacologica, Microbiologica et Immunologica Scandinavica*. 116:596-601.

Hwang, B.G., Park, I.C., Park, M.J., Moon, N.M., Choi, D.W., Hong, W.S., Lee, S.H. & Hong, S.I. (1997). Role of the nm23-H1 gene in the metastasis of gastric cancer. *Journal of Korean Medical Science*. 12:514-518

IARC (1994). Liver flukes and *Helicobacter pylori*. IARC working group on the evaluation of carcinogenic risks to human. *IARC Monographs on the Evaluation of Carcinogenic Risks to Human*. 61:1-241.

Isogaki, J., Shinmura, K., Yin, W., Arai, T., Koda, K., Kimura, T., Kino, I. & Sugimura, H. (1999). Microsatellite instability and K-ras mutations in gastric adenomas, with reference to associated gastric cancers. *Cancer Detection and Prevention Journal*. 23: 204-214.

- Isozaki, H., Tanaka, N., Tanigawa, N. & Okajima, K. (2000). Prognostic factors in patients with advanced gastric cancer with macroscopic invasion to adjacent organs treated with radical surgery. *Gastric Cancer*. 3:202-210.
- Jakszyn, P. & Gonzales, C.A. (2006). Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. *World Journal of Gastroenterology*. 12:4296-4303.**
- Jasani, B., Novelli, M., Ruschoff, J., Osamura, R.Y. (2010). HER2 status: What is the difference between breast and gastric cancer? *Dako Connection: Ask the expert*. 58-64.**
- Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C. & Thun, M.J. (2006) Cancer statistics, 2006. *CA A Cancer Journal for Clinicians*. 56:106-130
- Johnson, S.M., Groosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K.L., Brown, D., & Slack, F.J. (2005). RAS is regulated by the let-7 microRNA family. *Cell*. 120(5):635-647.
- Juhl, H., Downing, S.G., Wellstein, A., Czubayko, F. (1997) HER-2/neu is rate limiting for Ovarian Cancer Growth. *The Journal of Biological Chemistry*. 272(42):29482-29486.**
- Kandasami, P., Tan, W.J. & Norain, K. (2003). Gastric cancer in Malaysia: The need for early diagnosis. *Medical Journal of Malaysia*. 58(5):758-762.**
- Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O'Callaghan, C.J., Tu, D., Tebbutt, N.C., Simes, R.J., Chalchal, H., Shapiro, J.D., Robitaille, S., Price, T.J., Shepherd, L., Au, H., Langer, C., Moore, M.J. & Zalcberg, J.R. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *The New England Journal of Medicine*. 359(27):1757-1765.
- Katai, H. & Sano, T. (2005). Early gastric cancer: concepts, diagnosis, and management. *International Journal of Clinical Oncology*. 10:375-383.
- Kato, Y., Yashiro, M., Fuyuhiko, Y., Kashiwagi, S., Matsuoka, J., Hirakawa, T., Noda, S., Aomatsu, N., Hasegawa, T., Matsuzaki, T., Sawada, T., Ohira, M., and Hirakawa, K. (2011). Effects of acute and chronic hypoxia on the radiosensitivity of gastric and esophageal cancer cells. *Anticancer Research*. 31(10): 3369-3375.
- Keates, S., Keates, A.C., Warny, M., Peek, R.M., Murray, P.G. & C.P. Kelly. (1999). Differential activation of mitogen-activated protein kinases in AGS gastric epithelial cells by cag1 and cag-*Helicobacter pylori*. *Journal of Immunology*. 163:5552-5559.
- Kelley, J.R. & Duggan, J.M. (2003). Gastric cancer epidemiology and risk factors. *Journal of Clinical Epidemiology*. 56:1-9.
- Kennedy, B.J. (1970). T N M classification for stomach cancer. *Cancer*. 26(5):971-983

- Kihana, T., Tsuda, H., Hirota, T., Shimosato, H., Terasa, M. & Hirohashi S. (1991). Point mutation of c-Ki-ras oncogene in gastric adenoma and adenocarcinoma with tubular differentiation. *Japanese Journal of Cancer Research*. 82:308–14.
- Kim, A.W. & Richter, H.M. (2008). Zollinger Ellison syndrome. *Common Surgical Diseases*. IV:123-126.
- Kim, I.J., Park, J.H., Kang, H.C., Shin, Y., Park, H.W., Park, H.R., Ku, J.L., Lim, S.B. & Park, J.G.. (2003). Mutational analysis of BRAF and Kras in gastric cancers: absence of BRAF mutations in gastric cancers. *Human Genetic*. 114:118-120.
- Kimura, K., Nagasaka, T., Hoshizima, N., Sasamoto, H., Notohara, K., Takeda, M., Kominami, K., Iishii, T., Tanaka, N., and Matsubara, N. (2007). No duplicate *KRAS* mutation is identified on the same allele in gastric or colorectal cancer cells with multiple *KRAS* mutations. *The Journal of International Medical Research*. 35(8): 450-457.
- Kobori, O. & Oota, K. (1974). Mucous substance and enzyme histochemistry of non-neoplastic and neoplastic gastric epithelium in man. *Acta Pathologica Japonica*. 24:119-130.
- Koeppen, H.K.W., Wright, B.D., Burt, A.D., Quirke, P., McNicol, A.M., Dybdal, N.O., Sliwkowski, M.X. & Hillan, K.J. (2001). Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. *Histopathology*. 38:96-104.
- Kumar, V., Cotran, R.S. & Robbins, S.L. (2003). *Robbins Basic Pathology*. Philadelphia (PA): Elsevier Saunders.
- Kuraoka, K., Matsumura, S., Hamai, Y., Nakachi, K., Imai, K., Matsusaki, K., Oue, N., Ito, R., Nakayama, H., & Yasui W. (2003). A single nucleotide polymorphism in the transmembrane domain coding region of *her-2* is associated with development and malignant phenotype of gastric cancer. *International Journal of Cancer*. 107, 593-596.
- Lauren, P. (1965). The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. *Acta Pathologica, Microbiologica et Scandinavica*. 64:31-49.
- Lauren, P.A. & Nevalainen, J.T. (1993) Epidemiology of intestinal and diffuse types of gastric carcinoma: a new-trend study in Finland with comparison between studies from high and low-risk areas. *Cancer*. 71:2926-33.
- Lee, J.H., Cho, S.J., Zhang, X., Zheng, Z., Lee, E.S., Kim, A., Kim, Y.S., Chae, Y.S. & Ki, I. (2006). nm23-H1 protein expression and gene mutation in 150 patients with non-Hodgkin's lymphoma. *Journal of Korean Medical Science*. 21: 645-51.
- Lee, J.W., Soung, Y.H., Seo, S.H., Kim, S.Y., Park, C.H., Wang, Y.P., Park, K., Nam, S.W., Park, W.S., Kim, S.H., Lee, J.Y., Yoo, N.J. & Lee, S.H. (2006). Somatic

- mutations of ERBB2 kinase domain in gastric,, colorectal, and breast carcinomas. *Clinical Cancer Research*. 12(1):57-61.
- Lee, KE, Lee, HJ, Kim, YH, Yu, HJ, Yang, HK, Kim, WH, Lee, KU, Choe, KJ, Kim, JP. (2003). Prognostic significance of p53, nm23, PCNA, and c-erbB-2 in gastric cancer. *Japan Journal of Clinical Oncology*. 33(4):173-179.
- Lee, KH, Lee, JS, Suh, C, Kim, SW, Kim, SB, Lee, JH, Lee, MS, Park, MY, Sun, HS, Kim, SH. (1995). Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. *Cancer*. 75: 2794-2801.
- Leonard, J.P. and Coleman, M. (2006). *Hodgkin's and non-Hodgkin's lymphoma*. Springer. New York, USA
- Leone, A., Flatow, U., King, C.R., Sandeen, M.A., Margulies, I.M.K., Liotta, L.A. & Steeg, P.S. (1991). Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. *Cell*. 65:25–35
- Leong, T., Willis, D., Joon, D.L., Condrón, S., Hui, A. & Ngan, S.Y.K. (2005). 3D conformal radiotherapy for gastric cancer-results of a comparative planning study. *Radiotherapy and Oncology*. 74:301-306.
- Leung, W.K., Wu, M.S., Kakugawa, Y., Kim, J.J., Yeoh, K.G., Goh, K.L., Wu, K.C., Wu, D.C., Sollano, J., Kachintorn, U, Gotoda, T., Lin, J.W., You, W.C., Ng, K.W. & Sung, J.Y. (2008). Screening for gastric cancer in Asia: current evidence and practice. *The Lancet Oncology*. 9(3):279-287.
- Li, M., Liu, W., Zhu, Y.F., Chen, Y.L., Zhang, B.Z. & Wang, R. (2006). Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer. *Acta Oncologica*. 45:1115-1119.
- Lièvre, A., Bachet, J., Boige, V., Cayre, A., Le Corre, D., Buc, E., Yehou, M., Baouche, O., Landi, B., Louvet, C., Andre, T., Bibeau, F., Diebold, M., Rougier, P., Ducreux, M., Tomasic, G., Emile, J., Liorea, F.P., & Laurent-Puig, P. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. *Journal of Clinical Oncology*. 28(3):374-379.
- Liu, Z., Liu, L., Li, M., Wang, Z., Feng, L., Zhang, Q., Cheng, S. & Lu, S. (2011). Epidermal growth factor receptor mutation in gastric cancer. *Pathology*. 43(3):234-238.
- Liu, Z.M., Liu, L.N., Li, M., Zhang, Q.P., Cheng, S.H. & Lu, S. (2009). Mutation detection of KRAS by high-resolution melting analysis in Chinese with gastric cancer. *Oncology Reports*. 22:515-520.
- Lyke, J.C. & Lopez, P.P. (2004). Gastric cancer: Diagnosis and treatment options. *American Family Physician*. 69:1133-1140, 1145, 1146.

- Maehara, Y., Sakaguchi, Y., Moriguchi, S., Orita H., Korenaga, D., Kohnoe, S. & Sugimachi, K. (1992). Signet Ring Cell Carcinoma of the Stomach. *Cancer*. 69(7):1645-1651.
- Macfarlane, T.V. (2003). Editorial: Sample size determination for research projects. *Journal of orthodontics*. 30: 99-100.
- Malaysian cancer statistics-data and figure Peninsular Malaysia*; National Cancer Registry: Malaysia, 2006.
- Mandail, M.V., Konishik, I., Komatsu, T., Mon, T., Araol, S., Nomura, H., Kanda, Y., Hiai, H., & Fukumotol, M. (1995). Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression. *British Journal Cancer*. 72: 691-695.
- MAPK/Erk in growth and differentiation. (2009). Retrieved October 22, 2010, from http://www.cellsignal.com/reference/pathway/MAPK_ERK_Growth.html
- Marshall, J.C., Collins, J., Marino, N. & Steeg, P. (2010). The Nm23-H1 metastasis suppressor as a translational target. *European Journal of Cancer*. 46:1278-1282.
- Marshall, J.C., Lee, J.H., & Steeg, P.S. (2009). Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. *Molecular Cellular Biochemistry*. 329(1-2):115-20.
- Maryam, K., Askarzadeh, P., Shayanfar, N., Sadeghipour, A.R., Bahraminezhad, M. (2009). Interpretation of immunohistochemistry results of HER2/*neu* expression in invasive breast cancer: Evaluation of interobserver and intraobserver agreement. *Journal of Iran University of Medical Sciences*. 16 (62):147-155.
- Mattar, R., Marques, S.B., Monteiro, M.S., Santos, A.F., Iriya, K. & Carrilho, F.J. (2007). *Helicobacter pylori* cag pathogenicity island genes: clinical relevance for peptic ulcer disease development in Brazil. *Journal of Medical Microbiology*. 56:9-14.
- McNamara, D. & El-Omar, E. (2008). *Helicobacter pylori* infection and the pathogenesis of gastric cancer: A paradigm for host-bacterial interactions. *Digestive and Liver Disease*. 40:504-509.
- Meng, T.C., Lee, M.S. & Lin, M.F. (2000). Interaction between protein tyrosine phosphate and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. *Oncogene*. 19:2664-2677.
- Miettinen, M., Kitamura, Y., Hirota, S. & Kanakura, Y. (2004). *Gastrointestinal stromal tumor (GIST): from pathology to molecular target therapy*. Tokyo: Japan Scientific Societies Press.
- Milne, A.N. and Offerhaus, J.A. (2010). Early-onset gastric cancer: Learning lessons from the young. *World Journal of Gastrointestinal Oncology*. 2(2):59-64.

- Mita, H., Toyota, M., Aoki, F., Akashi, H., Maruyama, R., Sasaki, Y., Suzuki, H., Idogawa, M., Kashima, L., Yanagihara, K., Fujita, M., Hosokawa, M., Kusano, M., Sabau, S.V., Tatsumi, H., Imai, K., Shinomaru, Y. & Tokino, T. (2009). A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signalling and cancer cell growth. *BioMed Central Cancer*. 9(1):198
- Mohammed, I.A., Streutker, C.J. & Riddell, R.H. (2002). Utilization of Cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. *Modern Pathology*. 15(6):611-616.
- Monig, S.P., Nolden, B., Lubke, T., Pohl, A., Grass, G., Schneider, P.M. Dienes, H.P., Holshier, A.H. & Baldus, S.E. (2007). Clinical significance of nm23 gene expression in gastric cancer. *Anticancer Research*. 27:3029-3034.
- Müller, M., Schneiders, A., Hommel, G. & Gabbert, H.E. (1998). Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis. *American Cancer Society*. 83(12):2481-2487.
- Nakajima, T., Harashima, S., Hirata, M. & Kajitani, T. (1978). Prognostic and therapeutic values of peritoneal cytology in gastric cancer. *Acta Cytologica*. 22:225-229.
- Nguyen L.T., Uchida T., Murakami K., Fujioka T., and Moriyama M. (2008). *Helicobacter pylori* virulence and the diversity of gastric cancer in Asia. *Journal of Medical Microbiology*. 57(12):1445-1453.
- Nielsen, J.S., Jakobsen, E., Holund, B., Bertelsens, K. & Jakobsen, A. (2004). Prognostic significance of p53, HER-2, and EGFR overexpression in borderline and epithelial ovarian cancer. *International Journal of Gynecology Cancer*. 14: 1086-1096.
- Nilsson, C., Sillen, A., Eriksson, L., Strand, M., Enroth, H., Normark, S., Falk, P. & Engstrand, L. (2003). Correlation between cag pathogenicity island composition and *Helicobacter pylori*-associated gastroduodenal disease. *Infection and Immunity*. 71(11):6573-6581.
- Nishizawa, M. (1993). Present status and prospects for cancer screening. *Journal of Gastroenterology Mass Survey*. 78:100-103.
- Normal gastric mucosa. (n.d.). Retrieved August 17, 2011, from Wikimedia website: http://upload.wikimedia.org/wikipedia/commons/1/1c/Normal_gastric_mucosa_intermed_mag.jpg
- O'Leary, J.P., Tabuenca, A., and Capote, R. (2008). *The physiologic basis of surgery*. Lippincott Williams & Wilkins, PA, USA.
- Oda, I., Saito, D., Tada, M., Iishi, H., Tanabe, S., Oyama, T., Doi, T., Otani, Y., Fujisaki, J., Ajioka, Y., Hamada, T., Inoue, H., Gotoda, T. & Yoshida, S. (2006).

A multicenter retrospective study of endoscopic resection for early gastric cancer. *Gastric Cancer*. 9:262-270.

- Odicino, F.E., Bignotti, E., Rossi, E., Pasinetti, B., Tassi, R.A., Donzelli, C., Falchetti, M., Fontana, P., Grigolato, P.G. & Pecorelli, S. (2008). Her-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence *in situ* hybridization. *International Journal of Gynecological Cancer*. 18:14-21.
- Ohata, H., Oka, M., Yanaoka, K., Shimizu, Y., Mukoubayashi, C., Mugitani, K., Iwane, M., Nakamura, H., Tamai, H., Arii, K., Nakata, H., Yoshimura, N., Takeshita, T., Miki, K., Mohara, O. & Ichinose, M. (2005). Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. *Cancer Science*. 96(10):713-720.
- Okabe-Kado, J. (2002). Serum nm23-H1 protein as a prognostic factor in hematological malignancies. *Leukemia & Lymphoma*. 43:859-867.
- Ono, H., Kondo, H., Gotoda, T., Shirao, K., Saito, D., Yamaguchi, H., Hosokawa, K., Shimoda, T. & Yoshida, S. (2001). Endoscopic mucosal resection for treatment of early gastric cancer. *Gastrointestinal cancer*. 48:225-229.
- Osterheld, M.C., Laurini, R. & Saraga, E. (1998). Early gastric carcinoma with focal advanced cancer: A particular subtype of gastric carcinoma. *Human Pathology*. 29 (8): 815-819.
- Otsuka, Y., Niwa, Y., Ohmiya, N., Ando, N., Ohashi, A., Hirooka, Y. & Goto, H. (2004). Usefulness of magnifying endoscopy in the diagnosis of early gastric cancer. *Endoscopy*. 36(2):165-169.
- Ou, C.C., Hsu, S.C., Hsieh, Y.H., Tsouw, W.L., Chuang, T.C., Liu, J.Y. & Kao, M.C.(2008). Downregulation of HER2 by RIG1 involves the PI3/Akt pathway in ovarian cancer cells. *Carcinogenesis*. 29(2):299-306.
- Oue, N., Yoshida, K., Noguchi, T., Sentani, K., Kikuchi, A. & Yasui, W. (2007). Increased expression of h-prune is associated with tumor progression and poor survival in gastric cancer. *Cancer Science*. 98(8):1198-1205.
- Park, D.I., Yun, J.W., Park, J.H., Oh, S.J., Kim, H.J., Cho, Y.K., Sohn, C.I., Jeon, W.K., Kim, B.I., Yoo, C.H., Son, B.H., Cho, E.Y., Chae, S.W., Kim, E.J., Sohn, J.H., Ryu, S.H. & Sepulveda, A.R. (2006). Her-2/neu amplification is an independent prognostic factor in gastric cancer. *Digestive Diseases and Sciences*. 51:1371-1379.
- Parkin, DM, Bray, F, Ferlay, J, & Pisani, P (2005). Global cancer statistics, 2002. *CA: A Cancer Journal for Clinicians*. 55(2): 74-108.

- Podolsky, I., Lee, E., Cohen, R. & Petterson, W.L. (1989). Prevalence of *C. pylori* in healthy subjects and in patients with peptic disease. *Gastroenterology*. 96:394.
- Polanski, M. & Anderson, N.L. (2006). A list of candidate cancer biomarkers for targeted proteomics. *Biomarkers Insights*. 2:1-48.
- Press, M.F., Bernstein, L., Thomas, P.A., Meisner, L.F., Zhou, J.Y., Ma, Y., Hung, G., Robinson, R.A., Harris, C., El-Naggar, A., Slamon, D.J., Phillips, R.N., Ross, J.S., Wolman, S.R. & Flom, K.J. (1997). HER-2/neu gene amplification characterized by fluorescence *in situ* hybridization: poor prognosis in node-negative breast carcinomas. *Journal of Clinical Oncology*. 15:2894-904.
- Pritzker, K.P. (2002). Cancer biomarkers: easier said than done. *Clinical Chemistry*. 48:1147-1150.
- Pylorus mucosa (n.d.). Retrieved August 17, 2011, from Visual Photos website: http://www.visualphotos.com/image/2x3929861/pylorus_mucosa.
- Ramarao, N., Gray-Owen, S. D. & Meyer, T. F. (2000). *Helicobacter pylori* induces but survives the extracellular release of oxygen radicals from professional phagocytes using its catalase activity. *Molecular Microbiology*. 38:103-113.
- Ramelah, M., Alfizah, H., Isa, M.R, Mohd Rizah, A.M., Sheikh Anwar, A., Ismail, S., van Belkum, A. & Jasmi, A.Y. (2009). *Helicobacter pylori cagA* variants in Malaysians of different ethnicity. *European Journal of Clinical Infectious Disease*. 28:865-869.
- Ranzani, G.N., Renault, B., Pellegata, N.S., Fattorini, P., Magni, E., Bacci, F., & Amadori, D. (1993). Loss of heterozygosity and K-ras gene mutations in gastric cancer. *Human Genetics*. 92(3):244-249.
- Raufman, J.P. & Goldberg, E. (2009). *Textbook of Gastroenterology, fifth edition (Volume 1). Stomach and duodenum: anatomy and structural anomalies*. Hoboken, USA: Wiley-Blackwell.
- Riely, G.J., Marks, J. & Pao, W. (2009). KRAS mutations in non-small cell lung cancer. *Proceedings of the American Thoracic Society*. 6(2):201-205.
- Rinker-Schaeffer, C.W., O'Keefe, J.P., Welch, D.R & Theodorescu, D. (2006). Metastasis suppressor proteins: Discovery, molecular mechanisms and clinical application. *Clinical Cancer Research*. 12: 3882-3889.
- Roder, J.D., Bottcher, K., Busch, R., Wittekind, C., Her manek, P. & Siewert, J.R. (1998). Classification of regional lymph node metastasis from gastric carcinoma . *German Gastric Cancer Study Group*. 82:621-631.
- Rotterdam. H. & Enterline, H.T. (1989). Carcinoma of the stomach. Pathology of the stomach and duodenum. *New York: Springer-Verlag*. 142-204.

- Roukos, D.H., Agnantis, N.J., Fatouros, M. & Kappas, A.M. (2002). Gastric Cancer: Introduction, pathology, epidemiology. *Gastric Breast Cancer*. 1(1):1-3.
- Roukos, D.H.. (2010). Targeting gastric cancer with Trastuzumab: New clinical practice and innovative developments to overcome resistance. *Annals of Surgical Oncology*. 17:14-17.
- Rubin-Grandis, J., Melhem, M.F. & Barnes, E.L. & Tweardy, D.J. (1996). Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. *Cancer*. 78: 1284–1292.
- Ryu, J.W., Kim, H.J., Lee, Y.S., Myong, N.H., Hwang, C.H. & Lee, G.S., Yam, H.C. (2003). The proteomics approach to find biomarkers in gastric cancer. *Journal of Korean Medical Science*. 18:505-509.
- Salerno, M., Palmieri, D., Bouadis, A., Halverson, D. & Steeg, P.S. (2005). Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras 1 (KSR1) Erk scaffold in breast carcinoma cells. *Molecular Cell Biology* 25(4):1379-1388.
- Salomon, D.S., Brandt, R., Ciardiello, F. & Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. *Critical Reviews in Oncology/Hematology*. 19: 183–232.
- Sano, T., Tsujino, T., Yoshida, K., Nakayama, H., Haruma, K., Ito, H., Nakamura, Y., Kajiyama, G. & Tahara, E. (1991). Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. *Cancer Research*. 51: 2926-2931.
- Sant. M., Allemani. C., Santaquilani. M., Knijn. A., Marchesi. F. & Capocaccia, R. (2009). EURO CARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. *European Journal of Cancer*. 45(6):931-991.
- Sasano, N., Nakamura, K., Arai, M. & Akazaki, K. (1969). Ultrastructural cell patterns in human gastric carcinoma compared with non-neoplastic gastric mucosa-histogenetic analysis of carcinoma by mucin histochemistry. *Journal of the National Cancer Institute*. 43:783-802.
- Saxena, N., Lahiri, S.S., Hambarde, S. & Tripathi, R.P. (2008). RAS: Target for cancer therapy. *Cancer Investigation*. 26(9):936-947.
- Schneider, J., Pollán, M., Jiménez, E., Marenbach, K., Martínez, N., Volm, M., Marx, D., & Meden, H. (2000). nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma. *British Journal of Cancer*. 82(10): 1662-1670.
- Seeley, R., Stephens, T. & Tate, P. (2008). *Anatomy and physiology, Eight Edition*. New York: McGraw Hill.

- Seewald, S., Ang, T.L. & Soehendra, N. (2007). Endoscopic mucosal resection of Barrett's oesophagus containing dysplasia or intramucosal cancer. *Postgraduate Medical Journal*. 83(980):367-372.
- Segal, E.D., Cha, J., Lo, J., Falkow, S. & Tompkins, L.S. (1999). Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by *Helicobacter pylori*. *Microbiology*. 96(25):14559-14564.
- Semczuk, A., Postawki, K. & Prządka, D. (2004). Kras gene point mutations and p21ras immunostaining in human ovarian tumors. *European Journal of Gynaecology and Oncology*. 25:484-488.
- Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A. & Press, M.F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science*. 244:707-12.
- Smith, M.G., Hold, G.L., Tahara, E. & El-Omar, E.M. (2006). Cellular and molecular aspects of gastric cancer. *World Journal of Gastroenterology*. 12(19):2979-2990.
- Song, J.J., Lee, H., Kim, E., Kim, Y.S., Yoo, N.C., Roh, J.K., Kim, B.S. & Kim, J. (2000). Transduction effect of antisense K-ras on malignant phenotypes in gastric cancer cells. *Cancer Letters*. 157(1):1-7.
- Stahl, J.A., Loene, A., Rosengard, A.M., Porter, L., King, C.R. & Steeg, P.S. (1991). Identification of a second human nm23 gene, nm23-H2. *Cancer Research*. 51:445-9.
- StatTools (n.d.). Retrieved February 9, 2012, from StatTools website on unequal size: http://www.stattools.net/SSizunequal_Exp.php
- Stein, M., Rappuoli, R. & Covacci, A. (2000). Tyrosine phosphorylation of the *Helicobacter pylori* CagA antigen after cag-driven host cell translocation. *Microbiology*. 97(3):1263-1268.
- Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., Barthorpe, A., Blow, M., Brackenbury, L., Butler, A., Clarke, O., Cole, J., Dicks, E., Dike, A., Drozd, A., Edwards, K., Forbes, S., Foster, R., Gray, K., Greenman, C., Halliday, K., Hills, K., Kosmidou, V., Lugg, R., Menzies, A., Perry, J., Petty, R., Raine, K., Ratford, L., Shepherd, R., Small, A., Stephens, Y., Tofts, C., Varian, J., West, S., Widaa, S., Yates, A., Brasseur, F., Cooper, C.S., Flanagan, A.M., Knowles, M., Leung, S.Y., Louis, D.N., Looijenga, L.H., Malkowicz, B., Pierotti, M.A., Teh, B., Chenevix-Trench, G., Weber, B.L., Yuen, S.T., Harris, G., Goldstraw, P., Nicholson, A.G., Futreal, P.A., Wooster, R. & Stratton, M.R. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. *Nature*. 431:525-526.
- Suzuki, H., Miura, S., Imaeda, H., Suzuki, M., Han, J. Y., Mori, M., Fukumura, D., Tsuchiya, M. & Ishii, H. 1996. Enhanced levels of chemiluminescence and platelet

- activating factor in urease-positive gastric ulcers. *Free Radical Biology and Medicine*. 20: 449-454.
- Tahara, E. (1995). Molecular Biology of Gastric Cancer. *World Journal of Surgery*. 19:484-490.
- Tajiri, H., Doi, T., Endo, H., Nishina, T., Terao, T., Hyodo, I., Matsuda, K. & Yagi, K. (2002). Routine endoscopy using a magnifying endoscope for gastric cancer diagnosis. *Endoscopy*. 34(10):772-777.
- Tan, M., Yao, Y., & Yu, D. (1997).** Overexpression of the c-erbB-2 Gene Enhanced Intrinsic Metastasis Potential in Human Breast Cancer Cells without Increasing Their Transformation Abilities. *Cancer Research*. 57: 1199-1205.
- Tanner, M., Hollmen, M., Junttila, T.T., Kapanen, A.I., Tammola, S., Soini, Y., Helin, H., Salo, J., Joensuu, H., Sihvo, E., Elenius, K. & Isola, J. (2005). Amplification of HER-2 in gastric carcinoma: association with *Topoisomerase IIa* gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. *Annals on Oncology*. 16: 273-278.
- Tokunaga, A., Onda, M., Okuda, T., Teramoto, T., Fujita, I., Mizutani, T., Kiyama, T., Yoshiyuki, T., Nishi, K., Matsukura, N. (2006). Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. *Cancer*. 75(S6):1418-1425.
- Tsigris, C., Karayiannakis, A.J., Syrigos, K.N., Zbar, A., Diamantis, T., Kalahanis, N. & Alexious, D. (2002). Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer. *Anticancer Research*. 22:3061-3065.
- Uchino, S., Tsuda, H., Maruyama, K., Kinoshita, T., Sasako, M., Saito T., Kobayashi, M. & Hirobashi, S. (1993) Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with longterm survival of patients. *Cancer*. 72: 3179-84.
- Vakil, N. (2009). Editorial: H. pylori treatment: new wine in old bottles? *The American Journal of Gastroenterology* | doi:10.1038/ajg.2008.91
- Van-Cutsem, E., Kohne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J.K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J & Rougier, P. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *The New England Journal of Medicine*. 360(14):1408-1417.
- Vaughan, T.L., Davis, S., Kristal, A. & Thomas, D.B. (1995). Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric carcinoma: adenocarcinoma versus squamous cell carcinoma. *Cancer Epidemiology, Biomarkers & Prevention*. 4:85-92.

- Walker, W.A., Goulet, O., Kleinman, R.E., Sherman, P.M., Shneider, B.L., and Sanderson, I.R. (2004). *Pediatric gastrointestinal disease: Pathophysiology, diagnosis, and management*, 4th edition. BC Decker Publishers, Orlando, Canada.
- Wang T., Fox, J., and Giraud, A. (2009). *The biology of gastric cancers*. Springer, New York.
- Wang, C.S., Lin, K.H., Hsu, Y.C. & Hsueh, S. (1998). Distant metastasis of gastric cancer is associated with elevated expression of the antimetastatic nm23 gene. *Cancer Letters*. 128:23-29.
- Wang, S.E., Narasanna, A., Perez-Torres, M., Xiang, B., Wu, F.Y., Yang, S., Carpenter, G., Gazdar, A.F., Muthuswamy, S.K. & Arteaga, C.L. (2006). HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. *Cancer Cell*. 10(1):25-38.
- Wang, Z., Benerjee, S., Ahmad, A., Li Y., Azmi, A.S. Gunn, J.R., Kong, D., Bao, B., Ali, S., Gao, J., Mohammad, R.M., Miele, L., Korc, M., Sarkar, F.H. (2011). Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of notch and NF- κ B signalling pathways. *PLoS ONE*. 6(6):e02537.
- Watanabe, H., Jass, J.R. & Sobin, L.H. (1990). *World Health Organization (WHO). International histological classification of tumours: Histological typing of oesophageal and gastric tumors*. Germany: Springer-Verlag.
- Werner, M., Becker, K.F., Keller, G. & Hofler, H. (2001). Gastric adenocarcinoma: pathomorphology and molecular pathology. *Journal of Cancer Research on Clinical Oncology*. 127: 207-216.
- Wessler, S., Hocker, M., Fischer, W., Wang, T.C., Rosewicz, S., Haas, R., Wiedenmann, B., Meyer, T.F. & M. Naumann. (2000). *Helicobacter pylori* activates the histidine decarboxylase promoter through a mitogen-activated protein kinase pathway independent of pathogenicity island-encoded virulence factors. *Journal of Biology and Chemistry*. 275:3629-3636.
- Whitley E., and Ball, J. (2002). Statistic review 4: Sample size calculations. *Critical care*. 6:335-341.
- World Cancer Report 2008*; World Health Organization, International Agency for Research on Cancer: Lyon Cedex, France, 2008.
- World Health Organization* 2005. World Health Organization, Cancer Surveillance Database. Available at: www-dep.iarc.fr. Lyon Cedex, France, 2005.
- Xi, M.L., Jun, L. & Jun, W. (2009). The expression and significance of COX-2 and nm-23 in gastric carcinoma. *Progress in Modern Biomedicine*. 9(24):4712-4714.

- Yang, D., Tannenbaum, S.R., Buchi, G. & Lee, G.C. (1984). 4-Chloro-6-methoxyindole is the precursor of a potent mutagen (4-chloro-6-methoxy-2-hydroxy-1-nitroso-indolin-3-one oxime) that forms during nitrosation of the fava bean (*Vicia faba*). *Carcinogenesis*. 5:953-956.
- Yang, Y.Q., Wu, L., Chen, J.X., Sun, J.Z., Li, M., Li, D.M., Lu, H.Y., Su, Z.H., Lin, X.Q. & Li, J.C. (2008). Relationship between nm23H1 genetic instability and clinical pathological characteristics in Chinese digestive system cancer patients. *World Journal of Gastroenterology*. 14(36):5549-5556.
- Yeung, P., Lee, C.S., Marr, P., Sarris, M. & Fenton-Lee, D. (1998). Nm23 gene expression in gastric carcinoma: an immunohistochemical study. *Australian and New Zealand Journal of Surgery*. 68: 180-182.
- Yokoyama, H., Ikehara, Y., Kodera, Y., Ikehara, S., Yatabe, Y., Mochizuki, Y., Koike, M., Fujiwara, M., Nakao, A., Tatematsu, M. & Nakanishi, H. (2006). Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. *British Journal of Cancer*. 95:1504-1513.
- Yonemura, Y., Ninomiya, I., Ohoyama, S., Kimura, H., Yamaguchi, A., Fushida, S., Kosaka, T., Miwa, K., Miyazaki, I. & Endou, Y. (1991). Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. *Cancer*. 67: 2914-2918
- You, W., Zhang, L., Gail, M., Chang, Y., Liu, W., Ma, J., Li, J., Lin, M., Hu, Y., Yang, C., Blaser, M., Correa, P., Blot, W., Fraumeni, J.R. & Xu, G. (2000). Gastric dysplasia and gastric cancer: *Helicobacter pylori*, serum vitamin C, and other risk factor. *Journal of the National Cancer Institute*. 92(19):1607-1612.**
- Yuen, S.T., Davies, H., Chan, T.L., Ho, J.W., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Tsui, W.W., Chan, A.S., Futreal, P.A., Stratton, M.R., Wooster, R., and Leung, S.Y. (2002). Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. *Cancer Research*. 62:6451-6455.
- Zhang, X.L., Yang, Y.S., Xu, D.P., Qu, J.H., Guo, M.Z., Gong, Y. & Huang, J. (2009). Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. *World Journal of Surgery*. 33:2112-2118.
- Zhao, W., Chan, T.S., Chu, K.M., Chan, A.S., Stratton, M.R., Yuen, S.S. & Leung, S.Y. (2004). Mutations of *BRAF* and *KRAS* in gastric cancer and their association with microsatellite instability. *International Journal of Cancer*. 108: 167-169.